Medication info
DuoStar Tablet 40/10 Milligrams

DuoStar Tablet 40/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Celltrion Pharmaceutical Co., Ltd.
Appearance
Bright blue elliptical film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP*3]
Approval status
Active

MFDS item code 201906993 · Approved 2019.09.30 · Insurance code 693903140

Summary

Main use
Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease
Who takes it
Adults
Adult dose
This medication should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medication orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. 3. Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. A maintenance dose of 10 milligrams once daily is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medication is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Celltrion Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and dyslipidemia; inhibition of atherosclerosis progression; prevention of cardiovascular disease

  • Essential hypertension
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who need to take telmisartan and rosuvastatin simultaneously. Telmisartan primarily reduces the risk of death from myocardial infarction, stroke, and cardiovascular disease in patients with essential hypertension and those at high risk, particularly for patients over the age of 55. Rosuvastatin is effective for hypercholesterolemia, especially in cases where dietary therapy and exercise are insufficient, delaying atherosclerosis progression and reducing the associated cardiovascular risk. Additionally, this drug also helps lower the risk of stroke, myocardial infarction, and revascularization procedures. Therefore, this medication is used to reduce the risk of cardiovascular complications in patients with both hypertension and hyperlipidemia.

How to take

Adult dose

This medication should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of each component, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg of this medication orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg has not been established. 3. Patients with hepatic impairment Use with caution in patients with mild to moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. A maintenance dose of 10 milligrams once daily is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams once daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medication to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medication to patients with active liver disease. 5. Race: Because systemic exposure to this medication is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medication is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medication (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This medication can cause serious harm or risk of death to the fetus or newborn if administered to pregnant women, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients with allergies to any component of this medication or in those with specific liver, kidney, or muscle diseases. Elderly patients or those with impaired liver function should use it cautiously and should frequently monitor their health status, such as blood pressure or potassium levels. If symptoms of muscle pain or weakness occur, medical consultation should be sought promptly, and a blood test may be needed to check for muscle damage. This medication may affect liver function, so liver enzyme levels should be monitored regularly, and discontinuation is necessary if abnormalities are found. Additionally, this drug may interact with other medications, so patients should inform their healthcare providers of any other medications they are taking, particularly those with impaired kidney function. Pregnant or nursing women should not take this medication, and women of childbearing age should use appropriate contraceptive methods. In cases of overdose, symptoms such as low blood pressure, dizziness, and kidney problems may occur, requiring immediate medical attention. While taking this medication, be cautious of dizziness or drowsiness when driving or operating machinery. Keep out of reach of children and do not transfer to another container.

Side effects

Headache, positional dizziness, sleep paralysis, high blood pressure, low blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory impairment, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, shortness of breath, abdominal pain, diarrhea, dyspepsia, abdominal distension, vomiting, abdominal discomfort, dry mouth, liver dysfunction, liver disease, increased sweating, itching, rash, erythema, angioedema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, elevated serum creatinine, elevated serum uric acid, increased liver enzymes, elevated serum CK, decreased hemoglobin, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, palpitations, fatigue, nausea, inadequate effect, constipation, nausea, pancreatitis, pruritis, rash, urticaria, myopathy, rhabdomyolysis, weakness, facial swelling, myasthenia gravis, myasthenic syndrome, thrombocytopenia, elevated serum creatinine, acute kidney failure, oliguria, headache, dizziness, cough, dyspepsia, chest pain, myalgia, increased CK, elevated AST, weakness, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, fainting, generalized pain, muscle cramps, gout, erectile dysfunction, hypovolemia, hypotension, tachycardia, bradycardia, acute kidney failure, shock, loss of consciousness, liver dysfunction, jaundice, anaphylactoid symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, inadequate effect, headache, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial swelling, rash, alopecia, conjunctivitis, tinnitus, petechiae, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, edema, palpitations, fatigue, nausea, inadequate effect

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. Storing it this way will help preserve the medication's effectiveness and safety for a longer period.

Appearance and packaging

Appearance

Bright blue elliptical film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP*3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.